307 related articles for article (PubMed ID: 31758511)
41. Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml.
Witkowska-Patena E; Giżewska A; Dziuk M; Miśko J; Budzyńska A; Walęcka-Mazur A
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):343-348. PubMed ID: 31780781
[TBL] [Abstract][Full Text] [Related]
42. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K
Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
[TBL] [Abstract][Full Text] [Related]
43. The use of
Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
[TBL] [Abstract][Full Text] [Related]
44. PSMA-11 PET/CT for Detection of Recurrent Prostate Cancer in Patients With Negative Choline PET/CT.
Pinot F; Le Pennec R; Abgral R; Blanc-Béguin F; Hennebicq S; Schick U; Valeri A; Fournier G; Le Roux PY; Salaun PY; Robin P
Clin Genitourin Cancer; 2023 Apr; 21(2):248-257. PubMed ID: 36658064
[TBL] [Abstract][Full Text] [Related]
45. Early lesion detection with
Wondergem M; Jansen BHE; van der Zant FM; van der Sluis TM; Knol RJJ; van Kalmthout LWM; Hoekstra OS; van Moorselaar RJA; Oprea-Lager DE; Vis AN
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1911-1918. PubMed ID: 31230088
[TBL] [Abstract][Full Text] [Related]
46. Comparison of standard and delayed imaging to improve the detection rate of [
Schmuck S; Nordlohne S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):960-968. PubMed ID: 28280856
[TBL] [Abstract][Full Text] [Related]
47. Pilot study of the diagnostic utility of
Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST
Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
[TBL] [Abstract][Full Text] [Related]
48. Correlations between whole body volumetric parameters of
Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
[TBL] [Abstract][Full Text] [Related]
49. Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of
Chevalme YM; Boudali L; Gauthé M; Rousseau C; Skanjeti A; Merlin C; Robin P; Giraudet AL; Janier M; Talbot JN
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2935-2950. PubMed ID: 33416958
[TBL] [Abstract][Full Text] [Related]
50. An Australian experience using Tc-PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy.
Duncan I; Ingold N; Martinez-Marroquin E; Paterson C
Prostate; 2023 Jul; 83(10):970-979. PubMed ID: 37051636
[TBL] [Abstract][Full Text] [Related]
51. Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients.
Natarajan A; Agrawal A; Murthy V; Bakshi G; Joshi A; Purandare N; Shah S; Puranik A; Rangarajan V
World J Nucl Med; 2019; 18(3):244-250. PubMed ID: 31516367
[TBL] [Abstract][Full Text] [Related]
52. Comparison of
Li Y; Han D; Wu P; Ren J; Ma S; Zhang J; Song W; Lin X; Jiao D; Shi S; Yang F; Wu J; Meng P; Wen W; Kang F; Wang J; Qin W
Sci Rep; 2020 Jul; 10(1):10963. PubMed ID: 32620790
[TBL] [Abstract][Full Text] [Related]
53. A prospective comparative study of [
Gao X; Tang Y; Chen M; Li J; Yin H; Gan Y; Zu X; Cai Y; Hu S
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2177-2187. PubMed ID: 36811661
[TBL] [Abstract][Full Text] [Related]
54. Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.
Prasad V; Steffen IG; Diederichs G; Makowski MR; Wust P; Brenner W
Mol Imaging Biol; 2016 Jun; 18(3):428-36. PubMed ID: 27038316
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic Performance of
Esen B; Seymen H; Tarim K; Koseoglu E; Bolukbasi Y; Falay O; Selçukbiricik F; Molinas Mandel N; Kordan Y; Demirkol MO; Tilki D; Esen T
Eur Urol Focus; 2023 Sep; 9(5):832-837. PubMed ID: 37032281
[TBL] [Abstract][Full Text] [Related]
56. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients.
Carvalho J; Nunes P; Da Silva ET; Silva R; Lima J; Quaresma V; Figueiredo A
Arch Ital Urol Androl; 2021 Mar; 93(1):21-25. PubMed ID: 33754603
[TBL] [Abstract][Full Text] [Related]
57. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications.
Morawitz J; Kirchner J; Lakes J; Bruckmann NM; Mamlins E; Hiester A; Aissa J; Loberg C; Schimmöller L; Arsov C; Antke C; Albers P; Antoch G; Sawicki LM
Eur J Radiol; 2021 Mar; 136():109556. PubMed ID: 33485127
[TBL] [Abstract][Full Text] [Related]
58.
Haidar M; Abi-Ghanem AS; Moukaddam H; Jebai ME; Al Zakleet S; Al Rayess S; Akkawi AR; Kassas M; Tamim H; Hajj AE; Estrada-Lobato E; Osman MM; Shamseddine A
Sci Rep; 2022 Nov; 12(1):20500. PubMed ID: 36443430
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
60. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy.
Bashir U; Tree A; Mayer E; Levine D; Parker C; Dearnaley D; Oyen WJG
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):901-907. PubMed ID: 30617554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
